← Back to Search

Other

ADX-629 for Atopic Dermatitis

Phase 2

Recruiting

Research Sponsored by Aldeyra Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Mild, moderate, or severe atopic dermatitis, defined as an IGA score of ≥2 at Baseline

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from day 1 to day 90

Awards & highlights

Study Summary

This trial tests the safety and effectiveness of a new drug to treat adults with atopic dermatitis.

Who is the study for?

This trial is for adults over 18 with mild to severe atopic dermatitis, which they've had for at least six months. Participants must not be pregnant or breastfeeding and should agree to use effective contraception during the trial. People with unstable chronic diseases, significant health abnormalities, or serious kidney disease are excluded.Check my eligibility

What is being tested?

The study is testing ADX-629's safety and effectiveness in treating atopic dermatitis both alone and alongside standard care. It's a Phase 2 trial involving multiple centers where all participants will openly receive the treatment without being compared to a control group.See study design

What are the potential side effects?

Specific side effects of ADX-629 aren't listed here, but generally, treatments like this could cause skin reactions, irritation or discomfort at the application site if topical, as well as potential systemic effects depending on how it works in the body.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My skin condition is diagnosed as atopic dermatitis with a severity score of 2 or more.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from day 1 to day 90

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from day 1 to day 90

This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 1 to day 90 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adverse Event (AE) Query

Secondary outcome measures

Investigator Global Assessment (IGA) Score

Trial Design

1Treatment groups

Experimental Treatment

Group I: ADX-629Experimental Treatment1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Aldeyra Therapeutics, Inc.Lead Sponsor

29 Previous Clinical Trials

4,018 Total Patients Enrolled

Media Library

ADX-629 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05717920 — Phase 2

Atopic Dermatitis Research Study Groups: ADX-629

Atopic Dermatitis Clinical Trial 2023: ADX-629 Highlights & Side Effects. Trial Name: NCT05717920 — Phase 2

ADX-629 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05717920 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you elucidate on the security of ADX-629 for patient use?

"Our assessment of ADX-629's safety is an optimistic 2, as the clinical trials have only yielded limited evidence in support. Phase 2 suggests that it is relatively safe but there are no empirical results to suggest any efficacy yet."

Answered by AI

Is recruitment open for this clinical trial?

"Unfortunately, the records on clinicaltrials.gov denotes that this research has stopped looking for participants. Initially posted in February 1st of 2023 and last updated on the 6th, it is no longer accepting candidates; however, 242 other medical trials are in search of volunteers at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

2023. "A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05717920.

All > Seborrheic Dermatitis > Atopic Dermatitis